[
  {
    "ts": null,
    "headline": "FDA awards cancer drug approvals to AbbVie and MSD",
    "summary": "The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.",
    "url": "https://finnhub.io/api/news?id=9c23820bf213f9805c850c6509c405e1aa7de43595bfeef3e8a12fb3d2a15ebe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747337178,
      "headline": "FDA awards cancer drug approvals to AbbVie and MSD",
      "id": 134483574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.",
      "url": "https://finnhub.io/api/news?id=9c23820bf213f9805c850c6509c405e1aa7de43595bfeef3e8a12fb3d2a15ebe"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b90e42aa3cb349cb6115109de3be60958cf381ae8846bc0f28ee56921553de7d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747326720,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 134487702,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b90e42aa3cb349cb6115109de3be60958cf381ae8846bc0f28ee56921553de7d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer",
    "summary": "Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.",
    "url": "https://finnhub.io/api/news?id=2ec9f51c6ae3644e6c0b7cbb366a58cec865e1293d20852cd3ce5ca6ce2c3259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747312920,
      "headline": "AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer",
      "id": 134483575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.",
      "url": "https://finnhub.io/api/news?id=2ec9f51c6ae3644e6c0b7cbb366a58cec865e1293d20852cd3ce5ca6ce2c3259"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie stakes $335M on a startup’s RNAi drugs",
    "summary": "ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer.",
    "url": "https://finnhub.io/api/news?id=bcaa7b37db94ecf7a869a57c95e2f24d42aef986b5274e3c03f2b41fd793903f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747306800,
      "headline": "AbbVie stakes $335M on a startup’s RNAi drugs",
      "id": 134483576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer.",
      "url": "https://finnhub.io/api/news?id=bcaa7b37db94ecf7a869a57c95e2f24d42aef986b5274e3c03f2b41fd793903f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie expands siRNA push with $335m ADARx deal",
    "summary": "This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.",
    "url": "https://finnhub.io/api/news?id=6c793b1de7acba70a1991acee1a014fbe6b091f4aaa5e2dc3049343be79e6c0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747306160,
      "headline": "AbbVie expands siRNA push with $335m ADARx deal",
      "id": 134465679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.",
      "url": "https://finnhub.io/api/news?id=6c793b1de7acba70a1991acee1a014fbe6b091f4aaa5e2dc3049343be79e6c0a"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Roche’s MET protein expression detecting assay for NSQ-NSCLC",
    "summary": "Results from the LUMINOSITY study indicated that those with high c-Met protein expression achieved a 35% ORR.",
    "url": "https://finnhub.io/api/news?id=26b5d631becd55f995ad5439d954d5c52124bb9294a7b9a6a3ed47b0e074f659",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747300305,
      "headline": "FDA approves Roche’s MET protein expression detecting assay for NSQ-NSCLC",
      "id": 134465680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Results from the LUMINOSITY study indicated that those with high c-Met protein expression achieved a 35% ORR.",
      "url": "https://finnhub.io/api/news?id=26b5d631becd55f995ad5439d954d5c52124bb9294a7b9a6a3ed47b0e074f659"
    }
  },
  {
    "ts": null,
    "headline": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV",
    "summary": "NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. . ...",
    "url": "https://finnhub.io/api/news?id=82d1e369f3509f5d77d19891f7c0ce69d7f8845589d06e544a5ed9bab3842d83",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747287976,
      "headline": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV",
      "id": 134464505,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. . ...",
      "url": "https://finnhub.io/api/news?id=82d1e369f3509f5d77d19891f7c0ce69d7f8845589d06e544a5ed9bab3842d83"
    }
  }
]